Cell Line Development Market Size By Product (Reagents & Media, Equipment {Incubator, Centrifuge, Bioreactor, Storage Equipment, Microscope}, Accessories & Consumables), By Source (Mammalian, Non-Mammalian {Insects, Amphibians}), By Cell Line (Recombinant, Hybridomas, Continuous Cell Line, Primary Cell Line), By Application (Bioproduction, Drug Discovery, Toxicity Testing, Tissue Engineering, Research) Industry Analysis Report, Regional Outlook, Application Potential, Competitive Market Share & Forecast, 2020 – 2026

Published Date: Feb 2020  |  Report ID: GMI429  |  Authors: Sumant Ugalmugle, Rupali Swain

Report Format: PDF   |   Pages: 200   |   Base Year: 2019




Summary Table of Contents Industry Coverage Methodology

Industry trends

Cell Line Development Market size exceeded USD 4.2 billion in 2019 and is set to grow at around 12.5% CAGR between 2020 and 2026. The cell lines are used to study biological processes and retain stability of the formed tissues. These cell lines are used in production of vaccines, antibodies, artificial tissues and synthesis of biological components. Moreover, the cell lines play a crucial role in studying pathophysiological, physiological as well as differentiation process of specific cells.
 

Cell Line Development Market

Get more details on this report - Request Free Sample PDF
 

Cell Line Development Market Report Coverage
Report Coverage Details
Base Year: 2019 Market Size in 2019: 4.3 Billion (USD)
Historical Data for: 2015 to 2019 Forecast Period: 2020 to 2026
Forecast Period 2020 to 2026 CAGR: 12.5% 2026 Value Projection: 9.9 Billion (USD)
Pages: 200 Tables, Charts & Figures: 176
Geographies covered (17): U.S., Canada, Germany, UK, France, Italy, Spain, Russia, Japan, China, India, Australia, South Korea, Brazil, Mexico, South Africa, Saudi Arabia
Segments covered: Product, Source, Cell Line, Application and Region
Companies covered (26): GE Healthcare, Thermo Fisher Scientific, Lonza Group, Sigma-Aldrich Corporation, Wuxi AppTec, American Type Culture Collection, Corning, Sartorius Stedim Biotech GmbH, Selexis, Cobra Biologics, EuBiologics Co., Ltd., Vista Biologics, Cobra Biologics, Patheon, Paragon Bioservices, Samsung Biologics, Cyagen, Promocell, Abzena PLC, Bioceros, Catalent Inc., Epistem Holdings Plc, Cell for Cure, Apath LLC, Progenitor Cell Therapy (PCT), GVK BIO, NAEJA RGM Pharmaceuticals
Growth Drivers:
  • Growing vaccine production worldwide
  • Increasing cancer prevalence in developing countries
  • Growth in biotechnology industry across the globe
  • Innovations in biologics due to patent expiration
  • Rising demand for monoclonal antibodies in developed economies
  • Technological innovation in cell line development
Pitfalls & Challenges:
  • Complex regulatory landscape
  • Issues related to stem cell research

Request 15% Free Customization on this Report
 

Increasing prevalence of chronic diseases and technological advancements in biotechnology will upsurge the market progress

Increasing disease burden globally, due to adoption of sedentary lifestyle, lack of physical exercise, unhealthy dietary habits will primarily drive the market growth through 2020-2026. According to the American Cancer Society, there were around 729,000 cancer cases in 2018. Growing awareness among people regarding availability of advanced cancer treatments will upsurge the demand for biologics such as monoclonal antibodies and regenerative medicine. Moreover, extended application of cell line development in biotechnology will further accelerate the market progress.
 

Technological development in cell line production techniques will serve to be another key factor that will drive the market growth. The increasing demand of monoclonal antibodies for treatment of various types of cancers will favor the market growth. Monoclonal bodies need stable cell lines for their production, thus, increasing the demand for highly efficient cell line development processes. However, lack of clear regulatory guidelines pertaining to cell line development may hamper market growth over the analysis period.
 

Increasing bioproduction has led to rise in demand for disease specific cell lines

Global Cell Line Development Market By Equipment

Get more details on this report - Request Free Sample PDF


The cell line development market segment is bifurcated into reagents & media, equipment and accessories & consumables. Reagents and media segment accounted for more than USD 2.2 billion in 2019 as they enable determination of heterogeneity and mutation in the formed tissues. The regulated quantity of reagents in media formulation helps the cell culture to grow and develop desired cell line.
 

Moreover, rise in bioproduction such as vaccines and monoclonal antibodies will surge the demand for reagents and media required for cell line development and preservation. Growing demand for reagents and media with balanced salt solution such as PBS, DPBS, as well as other factors such as Gibco media, HEPES buffer among others to ensure healthy development of cell line will drive the market demand.
 

Mammalian cell line is the most widely used source for cell line production due to its ability to express complex proteins

Cell Line Development Market By Source

Get more details on this report - Request Free Sample PDF
 

The source segment includes mammalian and non-mammalian cell lines. The non-mammalian source is further divided into insects and amphibians. Mammalian source segment accounted for more than 70% cell line development market share in 2019 and will show similar growth in the forthcoming years. The enhanced expression system and cell line engineering for mammalian cell line is expected to foster the industry growth.
 

The mammalian cell line is formed by studying developmental biology as well as gene and protein interaction. These cell lines have ability to express complex protein units in monoclonal antibodies that are similar to humans and are widely used in cell culture. Additionally, adoption of mammalian cell lines due to easy adaptability with the human tissues & biological components and reduced risk of infection, will thus, drive market growth over the forecast timeframe.
 

Rising cases of viral and bacterial infections will increase the demand of recombinant cell lines

The cell line segment covers recombinant, hybridomas, continuous cell line and primary cell line. Recombinant cell lines segment held substantial revenue in 2019 and is anticipated to grow at 12.7% over 2020-2026. The recombinant cell lines consist of recombinant DNA that ensure stability. These cell lines are used in treatment of autoimmune, hematologic diseases, hormonal dysregulations and other such diseases.
 

The recombinant cell lines function by protein folding, post-translational modifications and glycosylation that ensure active protein production. Additionally, huge investments in R&D will further surge the demand for recombinant cell lines, leading to cell line development market growth.
 

Monoclonal antibodies and vaccines are the most commonly synthesized bioproducts that will accelerate the market progress

Bioproduction application accounted for USD 2 billion in 2019 and is estimated to show lucrative growth through 2026. Increasing demand for biological products in the treatment of various chronic and infectious diseases will foster segment growth during the coming years.
 

Moreover, the technological advancements resulting in the development of superior techniques for bioproduction will prove beneficial for the market growth. The cell lines required for bioproduction have the ability to produce complex & large proteins for ideal growth characteristics. The most common human cell lines used for bioproduction includes Chinese hamster ovary (CHO) cell line that results into production of stable recombinant biopharmaceutical proteins essential for biologics production. Such advancements will thus further augment the market demand.
 

Adoption of advanced technologies and growing investments in R&D activities will prove beneficial for the North American market expansion

North America cell line development market demand accounted for more than USD 1.4 billion revenue in 2019. Rising adoption of sedentary lifestyle along with surge in alcohol and tobacco consumption will increase the regional disease burden over the upcoming years. Availability of advanced technologies, necessary for large scale breeding of productive cell lines will favor the industry growth. Moreover, the increasing demand of biologics in cancer treatment and rising healthcare expenditure will further spur the regional market demand.
 

Prominent industry players operating in cell line development industry focus on delivering multiple solutions to sustain market competition

Few key players operating in the global cell line development market share are Thermo Fisher Scientific, American Type Culture Collection, Corning, Vista Biologics, Cobra Biologics, Patheon, Samsung Biologics and Promocell. The Key industry players are focus on inorganic strategies such as partnerships, mergers, and acquisitions as well as new cell line launches and advancements. This will help the companies to hold a global footprint and maintain their market position.
 

Some of the recent industry developments:

  • In October 2019, American Type Culture Collection announced launch of mouse cell line authentication service, in partnership with the National Institutes for Standards and Technology (NIST). This partnership has helped the company to expand its cell line business portfolio as well as its existing customer base.
     
  • In February 2017, Lonza entered a strategic partnership with Sanofi, to establish mammalian cell culture facilities for production of monoclonal antibodies in Switzerland. This strategy enabled the company to expand geographically and garner more revenue.

The cell line development market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD from 2015 to 2026, for the following segments:

Market Outlook By Product

  • Reagents & Media
  • Equipment
    • Incubator
    • Centrifuge
    • Bioreactor
    • Storage Equipment
    • Microscope
  • Accessories & Consumables

Market Outlook By Source

  • Mammalian
  • Non-Mammalian
    • Insects
    • Amphibians

Market Outlook By Cell Line

  • Recombinant
  • Hybridomas
  • Continuous Cell Line
  • Primary Cell Line

Market Outlook By Application

  • Bioproduction
  • Drug Discovery
  • Toxicity Testing
  • Tissue Engineering
  • Research

The above information is provided for the following regions and countries:

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Spain
    • Russia
  • Asia Pacific
    • Japan
    • China
    • India
    • South Korea
    • Australia
  • Latin America
    • Brazil
    • Mexico
  • Middle East & Africa
    • South Africa
    • Saudi Arabia

 

Frequently Asked Questions (FAQ) :

The reagents and media product segment was valued at over USD 2.2 billion in 2019, says a GMI report.
Recombinant cell lines segment held substantial revenue in 2019 and is anticipated to grow at 12.7% over 2020-2026.
The mammalian cell line is the most widely used source for cell line production due to its ability to express complex proteins.
According to this report, North America accounted for more than USD 1.4 billion market size in 2019.

Buy NowImmediate delivery available

Single User: $5,150 Access to only 1 person; cannot be shared; cannot be printed
Multi User: $7,150 Access for 2 to 5 users only within same department of one company
Enterprise User: $9,150 Access to a company wide audience; includes subsidiary companies or other companies within a group of companies

Need a Discount? Get in touch with us for special pricing

Request Discount

Connect with our sales team

GMIPulse Subscription Trial

Take a free trial of GMIPuse, our report store; designed to provide clients a range of market research services, all on a single platform.

Start Your Free Trial

Benefits of Association

Data Coverage & Quality

GMI reports provide the most comprehensive coverage of any focus industry, ensuring a holistic and deep understanding of the market, along with actionable and granular data. We also take pride in our commitment to quality and strive to ensure that our clients get their moneys worth.

Client Trust & Security

GMI maintains strict code of conduct as a business and is committed to ensure that the privacy and trust of our clients are always maintained. As an organization, we also strive to be fully compliant with privacy laws, PCI and information security guidelines.

Customer Service

Our customers rely on us to produce accurate, reliable and timely information. Service orientation is a key mission for us as an organization; our process is guided by the desire to ensure that our clients are provided the best possible solutions in optimal timeframe. GMI stands by its commitment to service, providing timely assistance in both pre-sales and post-sales support for our clients.

Chat with us
We use cookies to enhance your experience. By continuing to visit this site you agree to our use of cookies. More info X